According to previous reports, systemic administration of IFN-α in patients with Behcet’s disease and other immune-related disorders could help to upregulate Tregs and inhibit IL-17-expressing cells [27], [28], [29]. This evidence concerns the gene IFNA2 and Behcet disease.